Sabine Illsinger

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.

Journal: Journal of neuromuscular diseases

Published: August 27, 2026

Immune Cell-Specific SMN Expression and Sustained Immune Alterations in Treated Spinal Muscular Atrophy.

Immune Cell-Specific SMN Expression and Sustained Immune Alterations in Treated Spinal Muscular Atrophy.

Journal: The Journal of clinical investigation

Published: August 25, 2026

Retrospective analysis of serial lipoprotein(a) measurements in pediatric patients: Intraindividual variability and impact on risk stratification.

Retrospective analysis of serial lipoprotein(a) measurements in pediatric patients: Intraindividual variability and impact on risk stratification.

Journal: Journal of clinical lipidology

Published: February 08, 2026

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence.

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence.

Journal: Journal of neuromuscular diseases

Published: November 24, 2025

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.

Journal: The Lancet regional health. Europe

Published: June 28, 2024

Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.

Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.

Journal: Orphanet journal of rare diseases

Published: June 11, 2024

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial.

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial.

Journal: JAMA pediatrics

Published: April 08, 2024

5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2.

5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2.

Journal: Journal of neurology

Published: October 30, 2023

Anterior Spinal Artery Syndrome Due to Fibrocartilaginous Embolism-Case Report and Treatment Options.

Anterior Spinal Artery Syndrome Due to Fibrocartilaginous Embolism-Case Report and Treatment Options.

Journal: Neuropediatrics

Published: May 10, 2023

Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples.

Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples.

Journal: Journal of inherited metabolic disease

Published: May 06, 2023

Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany.

Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany.

Journal: Journal of neuromuscular diseases

Published: December 04, 2022

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.

Journal: Orphanet journal of rare diseases

Published: June 23, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026